Search
ROG.VX: MPDL3280a likely first in bladder, but market worth $100m as pricing already set
- Amit Roy
- Jul 13, 2015
- 1 min read
Roche's MPDL3280a in bladder cancer is likely to be first anti PD-1/PD-L1 in this setting, but competitors are setting the price and their data may not be as bad as it first appears
Comments